Intravitreal dexamethasone implants for non-infectious uveitis.
Matthew McCartneyPeter McCluskeySophia ZagoraPublished in: Clinical & experimental ophthalmology (2019)
In keeping with larger studies, the authors suggest that DEX implants may effectively control uveitis refractory to other therapy, while improving BCVA and CRT. In addition, DEX usage has demonstrably reduced systemic steroid burden within the observed cohort.
Keyphrases
- juvenile idiopathic arthritis
- ankylosing spondylitis
- soft tissue
- vascular endothelial growth factor
- high dose
- low dose
- diabetic retinopathy
- cardiac resynchronization therapy
- age related macular degeneration
- risk factors
- rheumatoid arthritis
- stem cells
- left ventricular
- endothelial cells
- cell therapy
- atrial fibrillation
- optical coherence tomography
- smoking cessation